Fig. 2
From: Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease
Experimental design. Early AD male mice were treated with a single dose of human neural stem cell-derived extracellular vesicles (EVs) via retro-orbital vein (RO) injection at ~ 1.5–2.5 months of age and behaviorally tested 1 month later. Late-stage AD male mice received 2 RO injections of EVs at 2-week intervals and began behavior testing 1 month after the second injection